Freenome, Inc.
Freenome is a blank check company formed to combine with one or more businesses. It has conducted organizational activities, completed its initial public offering and searched for a prospective business combination, but has no operating activities or operating revenues. Its focus is on healthcare, particularly life sciences and medical technology companies in North America or Europe. Freenome aims to take a target company public through a merger or other business combination, using cash, equity, debt or a combination as consideration. Freenome earns no operating revenue while it seeks a transaction. On December 5, 2025, it entered into a business combination agreement with Freenome Holdings, Inc. and two wholly owned merger subsidiaries; the transaction’s closing is subject to customary conditions and risks. Freenome is headquartered in Brisbane, California.
No SEC Form 4 filings for $FRNM in the last 30 days.
See all $FRNM insider activity →Cathie Wood's Ark Invest sold shares of Palantir (PLTR), Alphabet (GOOG), Shopify (SHOP), and others, while adding positions in biotech firms like Pacific Biosciences (PACB), Scribe Therapeutics (SCTX), and Freenome (FRNM). The trades occurred across several ARK ETFs, including ARK Innovation and ARK Genomic Revolution.
Cathie Wood's Ark Invest purchased shares of CoreWeave (CRWV), Scribe Therapeutics (SCTX), and Freenome (FRNM), all trading 28% to 57% below their highs. CoreWeave saw 113% revenue growth but remains unprofitable. Scribe Therapeutics focuses on gene silencing and has cash until 2029. Freenome gained FDA approvals for cancer screening tests and rose 7% post-purchase.
Freenome launched SimpleScreen Lung, a blood test for lung cancer screening in adults 50-80 with a 20+ pack-year smoking history. It can be ordered alone or with the FDA-approved SimpleScreen CRC. In a study, it achieved 85% sensitivity at 50% specificity and 99.8% NPV. Stage-specific sensitivities ranged from 82% to 94%. The company filed an 8-K with the SEC on October 20, 2026.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning FRNM (Freenome, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent FRNM coverage spans financial news, market movers and technology.
Likely upward pressure as Ark’s sizable buy signals confidence.
Ark's involvement could reinforce the recent rally.
The launch introduces a potentially revenue‑generating diagnostic product and validates Freenome's technology.
Potential upside as a prominent investor adds exposure.
This is a pre-earnings scheduling update that sets the catalyst window for FRNM’s next earnings print and related guidance discussion.
AlphAI scores every news story that mentions FRNM with an AI model for sentiment and relevance, and aggregates insider trades from Freenome, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Cathie Wood's Ark Invest sold shares of Palantir (PLTR), Alphabet (GOOG), Shopify (SHOP), and others, while adding positions in biotech firms like Pacific Biosciences (PACB), Scribe Therapeutics (SCTX), and Freenome (FRNM). The trades occurred across several ARK ETFs, including ARK Innovation and ARK Genomic Revolution.
Cathie Wood's Ark Invest purchased shares of CoreWeave (CRWV), Scribe Therapeutics (SCTX), and Freenome (FRNM), all trading 28% to 57% below their highs. CoreWeave saw 113% revenue growth but remains unprofitable. Scribe Therapeutics focuses on gene silencing and has cash until 2029. Freenome gained FDA approvals for cancer screening tests and rose 7% post-purchase.
Freenome launched SimpleScreen Lung, a blood test for lung cancer screening in adults 50-80 with a 20+ pack-year smoking history. It can be ordered alone or with the FDA-approved SimpleScreen CRC. In a study, it achieved 85% sensitivity at 50% specificity and 99.8% NPV. Stage-specific sensitivities ranged from 82% to 94%. The company filed an 8-K with the SEC on October 20, 2026.
ARK ETFs sold 670,746 shares of Personalised (PSNL) for $10.7M, bought 254,668 shares of Freenome (FRNM) for $3.1M, sold 59,477 shares of CareDx (CDNA) for $4M, and bought 29,416 shares of Scribe Therapeutics (SCTX) for $609K. These trades indicate ARK's strategic portfolio adjustments.
Freenome (FRNM) will release Q3 2026 results on Nov. 10 after market close, followed by a call at 1:30 PM PT. The company develops blood-based cancer detection tests, including SimpleScreen CRC for colorectal cancer.
Freenome updated its SimpleScreen CRC blood test, reporting 80.4% sensitivity at 90% specificity and improved advanced precancerous lesion detection. The company aims for regulatory clearance and increased adoption through Abbott sales.
Several biotech stocks reached 52-week highs on September 18, 2026. Vogenx (VOGX) shares surged to $38.41, driven by positive clinical trial results. HeartSciences (HSCS) rose 7% to $5.21, while HeartFlow (HTFL) increased 2% to $52.22. Freenome (FRNM) gained 5% to $17.25, and Halozyme (HALO) hit $112.66 after announcing a $1.3B offering.
OmniAb (OABI) +13% to $5.43, raising 2026 cash flow guidance to $49M-$53M. Freenome (FRNM) +4% to $16.03 after FDA approvals. Exelixis (EXEL) +$59.11, Q2 profit $212M. LifeStance (LFST) +$13.15, Q2 revenue +26% to $435.4M. Faeth (FTH) +$40.89, Q2 loss $16M.
Aethlon Medical (AEMD) reported a 12% narrower Q1 loss and progress in its Hemopurifier study, with shares up 17.5%. Quoin Pharmaceuticals (QNRX) surged 34% pre-market on positive QRX003 data and a $50M financing. Dogwood Therapeutics (DWTX) gained 12% as its Halneuron trial advances. Freenome (FRNM) rose 7% after FDA Breakthrough Device Designation for its lung cancer test.
Jefferies initiated coverage on Freenome (FRNM) with a 'Buy' rating and $17 price target, citing its cancer detection tests and partnerships. Shares rose 12% to $13.00. Freenome's lead product, SimpleScreen, competes in colorectal cancer testing. The company plans to expand into other cancers, with lung cancer next. Key milestones include FDA approvals and a U.S. launch this fall. Freenome is unprofitable but has $1.3B market cap. Jefferies' target implies 47% upside from $11.56 close.
